CN Patent

CN107750166B — Pd-l1拮抗剂组合治疗

Assigned to Merck Patent GmbH · Expires 2022-02-11 · 4y expired

What this patent protects

本发明公开了包含程序性死亡配体1受体(PD‑L1)的拮抗剂和另一种治疗剂的组合疗法，和所述组合疗法用于治疗癌症的用途。

USPTO Abstract

本发明公开了包含程序性死亡配体1受体(PD‑L1)的拮抗剂和另一种治疗剂的组合疗法，和所述组合疗法用于治疗癌症的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN107750166B
Jurisdiction
CN
Classification
—
Expires
2022-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.